Evofem Biosciences, Inc. (EVFM): Free Cash Flow

Operating cash flow minus capital expenditures for the same annual period and currency, computed by TickerFacts from the filed figures. A simple proxy, not a reported figure; a year without both inputs is left out.

-$2.00M

Year ended 2025-12-31

-$477.0K

Trailing 12 months to 2026-06-30

2013-12-31 Free Cash Flow (USD) 2025-12-31

Period ended	Free Cash Flow	Change YoY	Source filing
2025-12-31	-$2.00M	n/m	2026-03-11, From 2025-01-01
2024-12-31	-$3.90M	n/m	2026-03-11, From 2024-01-01
2023-12-31	-$8.97M	n/m	2025-03-24, From 2023-01-01
2022-12-31	-$70.75M	n/m	2024-03-27, From 2022-01-01
2021-12-31	-$149.61M	n/m	2023-04-27, From 2021-01-01
2020-12-31	-$107.08M	n/m	2022-03-10, From 2020-01-01
2019-12-31	-$55.26M	n/m	2021-03-04, From 2019-01-01
2018-12-31	-$56.51M	n/m	2020-03-12, From 2018-01-01
2017-12-31	-$19.25M	n/a	2019-03-01, From 2017-01-01
No annual figure between 2015-12-31 and 2017-12-31.
2015-12-31	-$38.14M	n/m	2018-02-26, From 2015-01-01
2014-12-31	-$9.59M	n/m	2017-03-23, From 2014-01-01
2013-12-31	-$12.93M	n/a	2016-03-29, From 2013-01-01

Free Cash Flow at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Free Cash Flow	Change YoY
Evofem Biosciences, Inc. (EVFM)	2025-12-31	-$2.00M	n/m
CASI Pharmaceuticals, Inc. (CASIF)	2025-12-31	-$20.77M	n/m
Sol-Gel Technologies Ltd. (SLGL)	2025-12-31	$275.0K	n/m
NewAmsterdam Pharma Co N.V. (NAMS)	2025-12-31	-$148.03M	n/m
Alumis Inc. (ALMS)	2025-12-31	-$370.18M	n/m
uniQure N.V. (QURE)	2025-12-31	-$178.40M	n/m
Entrada Therapeutics, Inc. (TRDA)	2025-12-31	-$129.55M	n/m
Celularity Inc (CELU)	2024-12-31	-$6.56M	n/m
Cue Biopharma, Inc. (CUE)	2025-12-31	-$21.86M	n/m

Compare EVFM, CASIF, SLGL, NAMS side by side · Screen every company in Pharmaceutical Preparations ↗